Announcing Positive Results of Saturn-2 Phase 3 Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
Read More

Revolutionizing treatment for patients in need

View Our Pipeline
Scroll To Discover
Young woman smiling. Young woman smiling. Young woman smiling.

About

We’re committed to delivering boundless therapeutic ingenuity

Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company that embodies the values of commitment, empowerment, and teamwork. We aim to bring novel therapeutics to patients across a range of diseases with limited treatment options.

Discover Tarsus

Pipeline

Novel therapies, beginning with the eye

For the millions of patients living with Demodex blepharitis, an FDA-approved treatment is on the horizon.

Learn about TP-03

News & Media

Here is the latest from Tarsus

05/27/2022 Tarsus to Present at the Jefferies 2022 Healthcare Conference
05/10/2022 Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements
05/06/2022 Tarsus to Present at Bank of America 2022 Healthcare Conference
Contact Tarsus

Please reach out to us using the form below.

General Information
Investor Relations
Opt in to be the first to receive the latest Tarsus news
Send
Contact Tarsus

Thank you for getting in touch! Someone from our team will respond shortly.